title: Phase II study of AMSA and doxorubicin to treat metastatic breast cancer.
abstract: Twenty-two evaluable patients with metastatic breast cancer were treated with a combination of 4-(acridinylamino)methanesulfon-m-anisidide (AMSA) and doxorubicin. All patients but one had received prior therapy with fluorouracil, cyclophosphamide, and methotrexate. Eight patients had partial responses (36%) with a median time to treatment failure of 6 months. Two patients (9%) showed minor responses, and their times to progression were 4 and 6 months. The response rates obtained with this drug combination were similar to those observed in earlier studies using doxorubicin alone.
mesh_terms: D000328:Adult; D000368:Aged; D000609:Aminoacridines / Q000008:administration & dosage; D000677:Amsacrine; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004317:Doxorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D013997:Time Factors
chemical_list: D000609:Aminoacridines; D000677:Amsacrine; D004317:Doxorubicin